Clinical Trial Update: Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients [Phase 1]

View source ↗

Summary

Phase 1 study of mycophenolate mofetil (CellCept) in pediatric kidney transplant patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Kidney Transplant | Phase 1 | Status: TERMINATED